Methods and compositions involving (S)-bucindolol

1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and bucindolol substantially free of its R-stereoisomer and an additional pharmaceutical agent, wherein the additional pharmaceutical agent is a nitric oxide (NO) enhancing agent.

2. The pharmaceutical composition of claim 1 , wherein the ratio of S-bucindolol to R-bucindolol in the composition is at least about 80:20 by weight.

3. The pharmaceutical composition of claim 2 , wherein the ratio of S-bucindolol to R-bucindolol in the composition is at least about 90:10 by weight.

4. The pharmaceutical composition of claim 3 , wherein the ratio of S-bucindolol to R-bucindolol in the composition is at least about 99:1 by weight.

5. The pharmaceutical composition of claim 1 , wherein the composition further comprises a second additional pharmaceutical agent, wherein the second additional pharmaceutical agent treats a symptom or condition related to a cardiovascular disease, a neurological disease, an infectious disease, an inflammatory disease, a neoplasm, a gastrointestinal disease, a genitourinary disease, a pulmonary disease, or an immune disease.

6. The pharmaceutical composition of claim 5 , wherein the second additional pharmaceutical agent comprises a beta-adrenergic receptor blocker.

7. The pharmaceutical composition of claim 1 , wherein the NO enhancing agent is a RAS inhibitor, a statin, a PDE5 inhibitor, a NO-conjugated drug, or a diazeniumdiolate.

8. The pharmaceutical composition of claim 7 , wherein the NO enhancing agent is a statin.

9. The pharmaceutical composition of claim 8 , wherein the statin is atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin calcium, and simvastatin.

10. A method of treating a patient comprising administering to said patient a therapeutically effective amount of a composition comprising bucindolol, wherein the composition is substantially free of the R-stereoisomer of bucindolol, wherein the patient exhibits the symptoms of or been diagnosed with a right ventricular heart failure, congestive heart failure, hypertension, angina, myocardial infarction, or cardiac arrhythmia and wherein the patient is a human and the composition comprises a dose of 40 mg to 200 mg of bucindolol, the dose being prescribed to be administered at least once daily over a period of at least 28 days.

11. The method of claim 10 , wherein the patient is in need of a beta-blocker.

12. The method of claim 11 , wherein the patient has exhibited the symptoms of or been diagnosed with mitral valve prolapse, hypertrophic obstructive cardiomyopathy, or acute dissecting aortic aneurysm.

13. The method of claim 10 , wherein the ratio of S-bucindolol to R-bucindolol in the composition is at least 80:20 by weight.

14. The method of claim 13 , wherein the ratio of S-bucindolol to R-bucindolol in the composition is at least 90:10 by weight.

15. The method of claim 14 , wherein the ratio of S-bucindolol to R-bucindolol in the composition is at least 99:1 by weight.

16. The method of claim 10 , wherein bucindolol is in a solid form.

17. The method of claim 16 , wherein the composition is administered twice daily.

18. The method of claim 17 , wherein the composition is administered orally.

19. The method of claim 10 , wherein the composition comprises 50 mg to 100 mg of bucindolol.

20. The bucindolol of claim 1 , wherein the bucindolol is in a salt form.

21. An oral pharmaceutical composition comprising a pharmaceutically acceptable carrier and bucindolol substantially free of its R-stereoisomer and an additional pharmaceutical agent, wherein the additional pharmaceutical agent is a beta-adrenergic receptor blocker.